Target intelligence / Profile preview

Influenza virus NS1A-binding protein (IVNS1ABP)

Target
IVNS1ABP
Molecular classification
Other (multifunctional RNA- and protein-interacting adaptor), Kelch-like protein family, BTB (POZ) domain-containing, Ubiquitin-like ligase-substrate adaptor
01

Overview

Influenza virus NS1A-binding protein (IVNS1ABP) is a multifunctional human protein that acts as an adaptor and regulator for protein and RNA complexes, notably interacting with influenza A virus non-structural protein 1 (NS1)[1][2]. It regulates several cellular processes, including pre-mRNA splicing (promoting alternative and viral mRNA splicing), mRNA nuclear export, and actin filament stabilization. Its BTB and Kelch domains mediate dimerization and facilitate binding to splicing machinery and cytoskeletal components[1]. IVNS1ABP plays an essential role in facilitating efficient viral gene expression, viral replication, and suppression of apoptosis during influenza A infection, while also participating in the negative regulation of protein ubiquitination and modulating the aryl hydrocarbon receptor pathway. It is implicated in human disease as a host factor in viral infections and in rare cases of primary immunodeficiency (Immunodeficiency 70)[1][2][3]. No drugs are currently known to directly target IVNS1ABP, nor are biomarkers or established mechanisms of action for drug targeting documented. The molecule is not a classic therapeutic target (e.g., receptor, enzyme) but is of interest as a host cofactor in infection biology[1][2].

Other names
ARA3FLARA3HSPC068KIAA0850KLHL39ND1NS-1NS1-BPNS1BPIMD70Aryl hydrocarbon receptor-associated protein 3Kelch-like family member 39NCX downstream gene 1
02

Biological functions

RNA splicingRegulation of alternative splicing (especially viral mRNA)mRNA nuclear exportRegulation of protein ubiquitinationActin cytoskeleton organization and stabilizationRegulation of cell death (apoptosis)Modulation of the aryl hydrocarbon receptor pathwayResponse to viral infection
03

Disease associations

Immunodeficiency (specifically Immunodeficiency 70)Infection (host factor in influenza infection)Possibly cancer (via actin regulation and E3 ubiquitin ligase modulation through suppression of tumor suppressors)
04

Safety considerations

No direct safety concerns documented; as a host factor, targeting could potentially affect mRNA processing and cell viability, especially in the context of viral infection or immune function

Beyond the preview

Go deeper on Influenza virus NS1A-binding protein (IVNS1ABP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza virus NS1A-binding protein (IVNS1ABP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call